Trial Profile

A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brontictuzumab (Primary) ; Tipiracil/trifluridine (Primary) ; Trifluridine
Indications Colorectal cancer
Focus Adverse reactions; Pharmacodynamics
Sponsors OncoMed Pharmaceuticals

18 Apr 2017 Status changed from recruiting to discontinued because the combination of brontictuzumab plus chemotherapy was not tolerable in this patient population, according to an OncoMed Pharmaceuticals media release.
20 Jan 2017 According to OncoMed Pharmaceuticals media release, the company has announced that first patient has been dosed.
20 Jan 2017 Status changed from planning to recruiting according to OncoMed Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com